Peter Loftus

The Wall Street Journal highlighted a U.S. Senate report on Gilead Sciences, Inc. (NASDAQ: GILD) saying that the pharmaceutical giant knew high prices for its Hepatitis C drug would put the medicine out of reach for many patients that needed the treatment. The company priced its Solvaldi...